Interpace Biosciences, which provides molecular diagnostic tests for thyroid cancer, withdrew its plans for an initial public offering on Wednesday. It had first filed in September 2026, and most recently in October 2026 filed to raise $20 million by offering 3.1 million shares at a price range of $6 to $7.
The Parsippany, NJ-based company was founded in 1986. It had planned to list on the Nasdaq under the symbol IDXG. Lake Street Capital Markets and Laidlaw & Company (UK) were set to be the joint bookrunners on the deal.


